Hologic, Inc. (NASDAQ:HOLX) Stake Lifted by North Star Asset Management Inc.

North Star Asset Management Inc. lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 0.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 249,594 shares of the medical equipment provider’s stock after buying an additional 1,722 shares during the period. North Star Asset Management Inc. owned approximately 0.11% of Hologic worth $18,532,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD increased its stake in Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares in the last quarter. Norges Bank purchased a new position in shares of Hologic in the fourth quarter worth approximately $217,529,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Hologic by 4.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after acquiring an additional 87,176 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Hologic by 117.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after acquiring an additional 1,168,564 shares in the last quarter. Finally, TD Asset Management Inc boosted its stake in Hologic by 2.0% in the 1st quarter. TD Asset Management Inc now owns 1,934,841 shares of the medical equipment provider’s stock worth $150,840,000 after purchasing an additional 37,136 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Insiders sold 18,280 shares of company stock valued at $1,469,973 in the last ninety days. Insiders own 1.75% of the company’s stock.

Hologic Price Performance

Shares of HOLX stock opened at $81.57 on Friday. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The company has a market capitalization of $19.04 billion, a P/E ratio of 41.62, a P/E/G ratio of 2.57 and a beta of 0.99. The stock has a 50 day moving average of $79.45 and a two-hundred day moving average of $76.63. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.93 earnings per share. As a group, equities analysts expect that Hologic, Inc. will post 4.09 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HOLX shares. Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. JPMorgan Chase & Co. upped their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Stephens restated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Finally, StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 10th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.